Table 1.

Patient characteristics

A. TMA Cohort (n = 53)
Variablen (%)Median (range)
Age (y)55 (25-75)
Tumor size (cm)10 (2-35)
Gender
    Male26 (49)
    Female27 (51)
Ethnicity
    Caucasian42 (79)
    Black5 (9)
    Hispanic4 (8)
    Asian2 (4)
Imatinib dose
    400 mg29 (57)
    600 mg3 (6)
    800 mg19 (37)
Primary tumor site
    Stomach23 (43)
    Small bowel18 (34)
    Colon5 (9)
    Esophagus2 (4)
    Mesenteric2 (4)
    Liver2 (4)
    Retroperitoneal1 (2)
No. metastatic sites per patient*
    01 (2)
    124 (45)
    225 (47)
    32 (4)
    41 (2)
Location of metastatic disease in patient cohort
    Liver37 (70)
    Peritoneum37 (70)
    Lung7 (13)
    Chest wall1 (2)
    Lymph node1 (2)
B. Pre-imatinib and post-imatinib clinical trial cohort (n = 12)
Variable
No. (%)
Median (range)
Age (y)56 (31-87)
Tumor size (cm)9 (1-22.5)
Gender
    Male6 (50)
    Female6 (50)
Ethnicity
    Caucasian6 (50)
    Black4 (34)
    Hispanic1 (8)
    Asian1 (8)
Site of disease
    Stomach6 (50)
    Small bowel4 (33)
    Colon0 (0)
    Mesentery1 (8)
    Liver1 (8)
    Metastasis4 (33)
Days of neoadjuvant imatinib therapy
    3 d5 (42)
    5 d3 (25)
    7 d4 (33)
  • * Many patients had multiple organ sites of metastasis.